# Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

> **NCT00176644** · PHASE2 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Transdermal Estradiol

## Key facts

- **NCT ID:** NCT00176644
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Treatment ineffective
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00176644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00176644, "Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00176644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*